532300 Stock Overview
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Wockhardt Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹546.30 |
| 52 Week High | ₹630.00 |
| 52 Week Low | ₹165.20 |
| Beta | 1.62 |
| 1 Month Change | 2.06% |
| 3 Month Change | 19.67% |
| 1 Year Change | 221.26% |
| 3 Year Change | 7.90% |
| 5 Year Change | 27.64% |
| Change since IPO | 179.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 532300 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -5.2% | -2.8% | -1.5% |
| 1Y | 221.3% | 54.9% | 45.0% |
Return vs Industry: 532300 exceeded the Indian Pharmaceuticals industry which returned 54.9% over the past year.
Return vs Market: 532300 exceeded the Indian Market which returned 45% over the past year.
Price Volatility
| 532300 volatility | |
|---|---|
| 532300 Average Weekly Movement | 8.2% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 532300 has not had significant price volatility in the past 3 months.
Volatility Over Time: 532300's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 2,740 | Murtaza Khorakiwala | www.wockhardt.com |
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules; and active pharmaceutical ingredients. The company’s biopharmaceutical products include Glaritus, a long-acting biosimilar glargine; Wosulin, a recombinant human insulin; Wepox, an r-DNA erythropoietin; human insulin; and Biovac-B, a hepatitis B vaccine.
Wockhardt Limited Fundamentals Summary
| 532300 fundamental statistics | |
|---|---|
| Market cap | ₹83.95b |
| Earnings (TTM) | -₹5.01b |
| Revenue (TTM) | ₹27.76b |
3.0x
P/S Ratio-16.8x
P/E RatioIs 532300 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532300 income statement (TTM) | |
|---|---|
| Revenue | ₹27.76b |
| Cost of Revenue | ₹12.38b |
| Gross Profit | ₹15.38b |
| Other Expenses | ₹20.39b |
| Earnings | -₹5.01b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -32.66 |
| Gross Margin | 55.40% |
| Net Profit Margin | -18.05% |
| Debt/Equity Ratio | 66.3% |
How did 532300 perform over the long term?
See historical performance and comparison